Tag Archives: rimabotulinumtoxinB

FDA Approves Myobloc (rimabotulinumtoxinB) Injection for Chronic Sialorrhea

Print this page LOUISVILLE, Ky., Aug. 26, 2019 /PRNewswire/ — US WorldMeds, LLC announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for Myobloc (rimabotulinumtoxinB) injection for the treatment of chronic sialorrhea in adults.1  Sialorrhea, or drooling, is defined as an excess spillage of saliva out of… Read More »